公开(公告)号：WO2022094388A2

公开(公告)日：2022-05-05

申请号：PCT/US2021/057539

申请日：2021-11-01

Applicant: NEUVOGEN, INC.

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd, Merrill ,  HUNDT, Matthias ,  LEWIS, Amritha, Balakrishnan ,  MOHLER, Kendall, M. ,  SHAWLER, Daniel, Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55538 ,  A61K2039/70 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/884 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001151 ,  A61K39/001152 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001195 ,  A61K39/39

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing colorectal cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (I) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (II) express or increase expression of one or more immunostimulatory factors by the cells, and/or (ill) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to driver mutations. Also provided herein are methods of making and preparing the colorectal cancer vaccine compositions and methods of use thereof.

公开(公告)号：WO2022232148A2

公开(公告)日：2022-11-03

申请号：PCT/US2022/026354

申请日：2022-04-26

Applicant: THINK THERAPEUTICS, INC.

Inventor： GIFFORD, David, Kenneth ,  CARTER, Brandon

IPC: C07K14/705 ,  A61K39/395 ,  A61P35/00 ,  C07K14/725 ,  C07K16/30 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K38/08 ,  A61K38/10 ,  A61K39/001152 ,  A61K39/001158 ,  A61K39/00116 ,  A61K48/00 ,  C07K7/06 ,  C07K7/08

Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

公开(公告)号：WO2022094391A2

公开(公告)日：2022-05-05

申请号：PCT/US2021/057543

申请日：2021-11-01

Applicant: NEUVOGEN, INC.

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd Merrill ,  HUNDT, Matthias ,  LEWIS, Amritha Balakrishnan ,  MOHLER, Kendall M. ,  SHAWLER, Daniel Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55538 ,  A61K2039/575 ,  A61K2039/70 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/884 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001151 ,  A61K39/001152 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001195 ,  A61K39/39

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing breast cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to driver mutations. Also provided herein are methods of making and preparing the breast cancer vaccine compositions and methods of use thereof.

公开(公告)号：WO2022094386A1

公开(公告)日：2022-05-05

申请号：PCT/US2021/057536

申请日：2021-11-01

Applicant: NEUVOGEN, INC. [US]/[US]

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd, Merrill ,  HUNTDT, Matthias ,  LEWIS, Amritha, Balakrishnan ,  MOHLER, Kendall, M. ,  SHAWLER, Daniel, Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55538 ,  A61K2039/575 ,  A61K2039/70 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/884 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001151 ,  A61K39/001152 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001195 ,  A61K39/39

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (I) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (II) express or increase expression of one or more immunostimulatory factors by the cells, and/or (ill) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to acquired tyrosine kinase inhibitor (TKI) resistance mutations, EGFR activating mutations, and/or (v) express modified ALK intracellular domain(s), and/or express one or more driver mutations. Also provided herein are methods of making and preparing the vaccine compositions and methods of use thereof.

公开(公告)号：WO2022079175A1

公开(公告)日：2022-04-21

申请号：PCT/EP2021/078462

申请日：2021-10-14

Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Inventor： ROSSI, Matteo ,  BELNOUE, Elodie ,  DEROUAZI, Madiha

IPC: A61K39/00 ,  A61P35/00 ,  A61K31/00 ,  A61K38/17 ,  C07K14/47 ,  A61K2039/55561 ,  A61K2039/6075 ,  A61K39/0011 ,  A61K39/001106 ,  A61K39/001109 ,  A61K39/001119 ,  A61K39/00115 ,  A61K39/001152 ,  A61K39/001166 ,  A61K39/00117 ,  A61K39/001182 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001189 ,  C07K2319/10

Abstract: The present invention provides a combination of an agonist of stimulator of interferon response cGAMP interactor (1) (STING) and a vaccine including specific antigens or antigenic epitopes, namely, a complex comprising a cell penetrating peptide, at least one antigen or antigenic epitope, and a TLR peptide agonist. Such a combination is particularly useful in medicine, in particular in the prevention and/or treatment of cancer. Moreover, the present invention also provides compositions, such as a pharmaceutical compositions and vaccines, which are useful, for example, in the prevention and/or treatment of cancer.

公开(公告)号：WO2021239980A2

公开(公告)日：2021-12-02

申请号：PCT/EP2021/064415

申请日：2021-05-28

Applicant: HUBRO THERAPEUTICS AS

Inventor： ERIKSEN, Henrik ,  ERIKSEN, Jon Amund

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/00 ,  A61K2039/70 ,  A61K39/0011 ,  A61K39/001103 ,  A61K39/001152 ,  C07K14/47 ,  C07K14/71

Abstract: There is disclosed a peptide capable of inducing an immune response against: a ASTE1 -1a frameshift mutant protein, wherein the peptide comprises at least 10 consecutive amino acids of SEQ ID NO: 26; a ΤΑΕ1β -1a frameshift mutant protein, wherein the peptide comprises at least 10 consecutive amino acids of SEQ ID NO: 27; a KIAA2018 -1a frameshift mutant protein, wherein the peptide comprises a immunogenic fragment of one of SEQ ID NOs: 9-12, wherein the fragment comprises at least 8 consecutive amino acids of one of one of SEQ ID NOs: 9-12; or a SLC22A9 - 1a frameshift mutant protein, wherein the peptide comprises at least 8 consecutive amino acids of one of SEQ ID NOs: 14-18. There is also disclosed a peptide mixture comprising a first and second peptide, each independently selected from one of the peptides described above and a peptide capable of inducing an immune response against a ΤΘΕβΕ2 -1a frameshift mutant protein.